- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07597655
Emotion Intensity Modulates Intention in ASD
Emotional Expression Intensity Modulates Intention Understanding in Children With ASD: Evidence From Eye Tracking and Hidden Markov Modeling
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 611731
- School of Foreign Languages, University of Electronic Science and Technology of China
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Typically developing children without any developmental or neurological disorders.
Confirmed clinical diagnosis of Autism Spectrum Disorder and reconfirmed by the criteria of the Diagnostic Observation Table for ASD, Second Edition (ADOS-2).
Confirmed clinical diagnosis of Intellectual Disability and the ADOS-2 with a comparison score below the ASD diagnostic cut-off score (comparison score≤2).
Exclusion Criteria:
- Normal or corrected-to-normal vision, no color vision deficiencies, and legal guardian provided written informed consent.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Autism Spectrum Disorder (ASD) Group
|
|
Typically Developing (TD) Group
|
|
Intellectual Disability(ID)Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The visitation rate of the AOI
Time Frame: From second 3 to second 30 of the experimental stimulus.
|
Number of times the gaze enters the AOI per unit time.
It measures how frequently the AOI is re-visited.
Higher rates indicate repeated returns, reflecting high interest or difficulty disengaging; lower rates suggest rare or brief attention.
|
From second 3 to second 30 of the experimental stimulus.
|
|
The proportions of fixation duration
Time Frame: During the full 40 seconds video presentation.
|
fixation duration on an AOI ÷ total fixation duration (or across multiple AOIs).
It measures the relative amount of attention allocated to a specific area.
Higher proportions indicate prioritized or deeper processing of that region.
|
During the full 40 seconds video presentation.
|
|
The first fixation latency
Time Frame: During the full 40 seconds video presentation.
|
The First Fixation Latency = time from TOI onset until the first fixation lands on a predefined object.
It measures how fast attention is initially drawn to that object.
Shorter latencies indicate higher salience or more efficient search.
|
During the full 40 seconds video presentation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The face fixation transition ratio
Time Frame: From second 13 to second 15 of the experimental stimulus.
|
Number of gaze transitions from any non-face AOI to a face ÷ total number of gaze transitions.
It measures how often attention shifts toward faces.
Higher ratios indicate stronger social orienting or difficulty disengaging from faces.
|
From second 13 to second 15 of the experimental stimulus.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UESTC-GazeLab-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intellectual Disability
-
Oasi Research Institute-IRCCSNot yet recruitingMild Intellectual DisabilityItaly
-
GalenusRx, Inc.CP UnlimitedNot yet recruitingDevelopmental Disability | Intellectual Disability, Mild | Intellectual Disability, Mild to ModerateUnited States
-
Oasi Research Institute-IRCCSNot yet recruiting
-
Oasi Research Institute-IRCCSNot yet recruitingMild Intellectual DisabilityItaly
-
Oasi Research Institute-IRCCSNot yet recruiting
-
University of ExtremaduraUniversity of CadizCompletedDisability Physical | Disabilities Multiple | Disability, Intellectual | Disability Hearing | Disability, VisionSpain
-
Temple UniversityUniversity of Florida; University of Minnesota; University of New HampshireNot yet recruitingDevelopmental Disability | Intellectual Disability, Mild to ModerateUnited States
-
University of California, San FranciscoKorea Health Industry Development Institute; DoBrain Inc.CompletedMild Intellectual Disability | Borderline Intellectual FunctioningUnited States
-
KoraalUniversity of Amsterdam; Zuyd University of Applied SciencesCompletedMild Intellectual Disability | Borderline Intellectual FunctioningNetherlands
-
Vestvagoy MunicipalityUniversity of Oslo; University of TromsoActive, not recruitingDisability, Developmental | Disabilities, IntellectualNorway